Inhibition of rat heart allograft rejection by a PUVA treatment of the graft recipient
β Scribed by H. Oesterwitz; S. Gruner; W. Diezel; W. Schneider
- Publisher
- Springer
- Year
- 1990
- Tongue
- English
- Weight
- 967 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0934-0874
No coin nor oath required. For personal study only.
β¦ Synopsis
Treatment of rat heart grafts with PUVA, the combination of the photosensitizer 8-methoxypsoralen and longwave ultraviolet light, leads to a prolonged transplant survival in allogeneic recipients. A PUVA treatment of the recipient rats, performed for 7 consecutive days after transplantation, prolonged graft survival even more effectively. This may be due to the systemic immunomodulatory effects of PUVA in the recipient. One of the mediators is urocanic acid, which is transformed by ultraviolet light in the skin from its trans- to the cis-isomer, which, in turn, acts as a mediator on the immune system. An injection of cisurocanic acid into graft recipients for 7 consecutive days after transplantation resulted in prolonged graft survival; in 40% of the rats, permanent graft acceptance was observed. The significance of these results for clinical organ transplantation is discussed.
π SIMILAR VOLUMES
Sulphasalazine (SASP) is an immunomodulatory compound with disease-modifying activity in ulcerative colitis and in other autoimmune disorders. SASP was previously shown to prolong the survival of heart allografts in rats treated with cyclosporin A (CyA) for 9 days after transplantation. We have now